The US Biomedical R&D Authority has awarded Israel’s Atox Bio $24 million to develop its treatments for severe infections.  Atox Bio’s AB103 uniquely modulates the patient’s immune response rather than attacking the virus or bacteria. Pathogens cannot develop resistance to the treatment.

http://www.timesofisrael.com/israels-atox-gets-24m-to-fight-zombie-bio-threats/

http://www.globes.co.il/en/article-atox-bio-awarded-24m-to-fight-bio-threats-1000975287